National Institute of Mental Health (NIMH)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Mental Health (NIMH) sits in the top decile of US sponsors by registered trial count (#103 of 15,742 sponsors by registered trial count).
National Institute of Mental Health (NIMH): 343 sponsored US clinical trials, 42 recruiting.
National Institute of Mental Health (NIMH) sponsors 343 registered US clinical trials on ClinicalTrials.gov, 42 of them currently recruiting, and 256 completed. 29 of these trials are in Phase 3-4 (later-stage) and 106 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 21 trials.
Top-decile sponsor footprint
National Institute of Mental Health (NIMH) ranks in the top decile of sponsors by registered trial count (#103 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
256 of 296 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
343 total, page 5 of 7
PET Imaging of Dopamine in Healthy Study Participants
NCT00062946
Generalized Anxiety Disorder and Social Anxiety Disorder: Their Impact on the Processing of Information and Learning
NCT00062517
The Effects of Estrogen Withdrawal on Mood Symptoms in Women
NCT00060736
Brain Regulation of Emotions in People With Depression and Anhedonia
NCT00059579
Clinical Trial of Estrogen for Postpartum Depression
NCT00059228
Brain Imaging of Serotonin Transporters in the Brain
NCT00059046
Effects of Modafinil on Brain Function in Patients With Schizophrenia
NCT00057707
Screening Evaluation for Women With Postpartum Depression
NCT00056901
Expectation of Unpleasant Events in Anxiety Disorders
NCT00055224
Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies
NCT00055575
Effect of Hydrocortisone on the Brain
NCT00055003
Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia
NCT00061789
Riluzole to Treat Depression in Bipolar Disorder
NCT00054704
Brain Imaging in Depression
NCT00050700
Evaluation of Stress Disorders
NCT00050804
Brain Imaging Changes in Fear and Anxiety
NCT00047853
Screening for Childhood-Onset Psychotic Disorders
NCT00049738
MRI Study of Brain Activity and Risk for Depression in Adolescents
NCT00047944
The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease
NCT00046358
Brain Receptor Function in Post-Traumatic Stress Disorder
NCT00046553
Characterization of Childhood-Onset Obsessive-Compulsive Disorder
NCT00044239
Psychopharmacology of Fear-Potentiated Startle in Humans
NCT00044096
Clinical Trial of Mifepristone for Bipolar Depression
NCT00043654
Clinical Trial of Tolcapone for Cognition in Schizophrenia
NCT00044083
Examination of a Soy-Based Supplement for Major Depression
NCT00042380
Effects of Yohimbine and Naltrexone on Sexual Function
NCT00042536
Clinical Trial of Memantine for Major Depression
NCT00040261
Ethnic Variations in Antidepressant Response
NCT00047671
Brain Imaging in Alzheimer's Disease
NCT00039702
Effects of Hydrocortisone in Patients With Post-Traumatic Stress Disorder
NCT00039715
Clozapine vs. Placebo in Treatment-Refractory Bipolar Disorder in Children and Adolescents
NCT00036582
Serotonin Function During Depression
NCT00033787
Effect of D-cycloserine on Extinction of Fear Conditioning
NCT00352586
Clinical Trial of Felbamate for Treatment-Resistant Bipolar Depression
NCT00034229
PET Scanning in Parkinson s Disease
NCT00024622
Effects of Stress Hormones on Emotion and Cognition
NCT00032838
Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression
NCT00031317
Raloxifene and Rimostil for Perimenopause-Related Depression
NCT00030147
Reward-Related Processes and Brain Function
NCT00029588
Cortical Excitability in Obsessive-Compulsive and Related Disorders
NCT00029068
Clozapine for Treatment-Resistant Mania
NCT00029458
Brain Receptors in Sympathetic Nervous System Regulation
NCT00029627
The Treatment of Children and Adolescents With Treatment-Resistant Depression
NCT00029640
Evaluation of Age- and Alzheimer's Disease-Related Memory Disorder
NCT00029120
Ventilatory Physiology in Children at Risk for Anxiety
NCT00101777
Examination of Tamoxifen in Acute Mania in Patients With Bipolar I Disorder
NCT00026585
Behavior in Children With Attention Deficit Hyperactivity Disorder and in Healthy Volunteers
NCT00026546
Riluzole to Treat Major Depression
NCT00026052
Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder
NCT00025974
Brain Function in Mentally Ill Adolescents
NCT00025857
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 61 |
| Phase 2 | 45 |
| Phase 3 | 8 |
| Phase 4 | 21 |
Therapeutic Areas
What is open in the National Institute of Mental Health (NIMH) pipeline
42 recruiting of 343 indexed (12% open); 256 completed (75%).
Phase mix: 29 late (III/IV) vs 106 early (I/II) (early-phase heavy).
Top condition: Healthy (21 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Mental Health (NIMH): open-pipeline peers nationwide
Peers matched on 343 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
National Institute of Mental Health (NIMH) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 343 trials (± recruiting share)
- Children's Oncology Group · 342 trials · 10% recruiting
- Montefiore Medical Center · 345 trials · 19% recruiting
- Ohio State University Comprehensive Cancer Center · 341 trials · 23% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Augusta University · 12% recruiting · 106 trials
- University of Iowa · 12% recruiting · 228 trials
- Daiichi Sankyo · 12% recruiting · 236 trials
- Friends Research Institute · 12% recruiting · 41 trials
Related
What to do with this National Institute of Mental Health (NIMH) page
343 registered trials is a research-attention snapshot, not an endorsement of National Institute of Mental Health (NIMH) or any single study.
- 42 of National Institute of Mental Health (NIMH)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition National Institute of Mental Health (NIMH) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Mental Health (NIMH) pipeline card: 343 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.